PURPOSE: Neuromyelitis optica (NMO) is a chronic inflammatory demyelinating disease of the central nervous system (CNS). The pathogenesis of NMO remains unclear. IL-32 is emerging as a critical molecule in the pathophysiology of immune-mediated chronic inflammatory diseases. Whether IL-32 levels are elevated in NMO patients is unclear. We aimed to determine whether IL-32 levels are elevated in NMO patients and explore its relationship with IL-6, IL-17, and Expanded Disability Status Scale (EDSS) scores. METHODS: Plasma IL-32α, IL-6 and IL-17A were measured by enzyme-linked immunosorbent assay in NMO (n = 26), MS (n = 23) and 22 healthy controls. RESULTS: We found IL-32α levels were higher in NMO patients compared with MS (p = 0.020) and healthy controls (p = 0.00001). IL-32α levels were increased in MS patients compared with controls (p = 0.009). IL-32α positively correlated with IL-6 and IL-17A levels and EDSS scores in NMO patients. CONCLUSIONS: In summary, plasma IL-32α levels are associated with inflammatory responses in NMO patients.
PURPOSE:Neuromyelitis optica (NMO) is a chronic inflammatory demyelinating disease of the central nervous system (CNS). The pathogenesis of NMO remains unclear. IL-32 is emerging as a critical molecule in the pathophysiology of immune-mediated chronic inflammatory diseases. Whether IL-32 levels are elevated in NMO patients is unclear. We aimed to determine whether IL-32 levels are elevated in NMO patients and explore its relationship with IL-6, IL-17, and Expanded Disability Status Scale (EDSS) scores. METHODS: Plasma IL-32α, IL-6 and IL-17A were measured by enzyme-linked immunosorbent assay in NMO (n = 26), MS (n = 23) and 22 healthy controls. RESULTS: We found IL-32α levels were higher in NMO patients compared with MS (p = 0.020) and healthy controls (p = 0.00001). IL-32α levels were increased in MS patients compared with controls (p = 0.009). IL-32α positively correlated with IL-6 and IL-17A levels and EDSS scores in NMO patients. CONCLUSIONS: In summary, plasma IL-32α levels are associated with inflammatory responses in NMO patients.
Authors: Bas Heinhuis; Marije I Koenders; Piet L van Riel; Fons A van de Loo; Charles A Dinarello; Mihai G Netea; Wim B van den Berg; Leo A B Joosten Journal: Ann Rheum Dis Date: 2010-12-27 Impact factor: 19.103
Authors: Michel Varrin-Doyer; Collin M Spencer; Ulf Schulze-Topphoff; Patricia A Nelson; Robert M Stroud; Bruce A C Cree; Scott S Zamvil Journal: Ann Neurol Date: 2012-07-17 Impact factor: 10.422
Authors: Chris H Polman; Stephen C Reingold; Brenda Banwell; Michel Clanet; Jeffrey A Cohen; Massimo Filippi; Kazuo Fujihara; Eva Havrdova; Michael Hutchinson; Ludwig Kappos; Fred D Lublin; Xavier Montalban; Paul O'Connor; Magnhild Sandberg-Wollheim; Alan J Thompson; Emmanuelle Waubant; Brian Weinshenker; Jerry S Wolinsky Journal: Ann Neurol Date: 2011-02 Impact factor: 10.422